Your browser is no longer supported. Please, upgrade your browser.
Settings
ALPN [NASD]
Alpine Immune Sciences, Inc.
Index- P/E- EPS (ttm)-1.56 Insider Own1.90% Shs Outstand23.87M Perf Week-8.70%
Market Cap220.78M Forward P/E- EPS next Y-1.09 Insider Trans-73.67% Shs Float17.27M Perf Month-24.05%
Income-33.10M PEG- EPS next Q-0.40 Inst Own57.70% Short Float3.65% Perf Quarter-33.91%
Sales11.40M P/S19.37 EPS this Y41.20% Inst Trans4.67% Short Ratio6.05 Perf Half Y-16.49%
Book/sh2.23 P/B3.95 EPS next Y21.00% ROA-24.90% Target Price- Perf Year135.56%
Cash/sh3.86 P/C2.28 EPS next 5Y- ROE-66.40% 52W Range3.60 - 16.37 Perf YTD-30.08%
Dividend- P/FCF9.60 EPS past 5Y-12.60% ROI-39.80% 52W High-46.18% Beta1.62
Dividend %- Quick Ratio2.30 Sales past 5Y80.10% Gross Margin- 52W Low144.63% ATR0.73
Employees57 Current Ratio2.30 Sales Q/Q190.90% Oper. Margin- RSI (14)33.49 Volatility4.31% 7.83%
OptionableYes Debt/Eq0.19 EPS Q/Q-49.80% Profit Margin- Rel Volume0.99 Prev Close8.98
ShortableYes LT Debt/Eq0.12 EarningsMay 13 AMC Payout- Avg Volume104.20K Price8.81
Recom1.50 SMA20-19.26% SMA50-22.19% SMA200-18.12% Volume102,958 Change-1.89%
Dec-21-20Initiated H.C. Wainwright Buy $21
Aug-26-20Initiated Cowen Outperform
Jun-08-21 08:00AM  
01:12AM  
Jun-04-21 04:05PM  
Jun-03-21 08:14AM  
01:20AM  
Jun-02-21 04:05PM  
08:00AM  
May-23-21 06:43AM  
May-20-21 04:47AM  
May-19-21 05:10PM  
May-18-21 04:05PM  
May-13-21 06:45PM  
04:05PM  
May-06-21 03:00PM  
May-05-21 01:41AM  
Apr-28-21 04:05PM  
Apr-16-21 08:28AM  
Apr-12-21 08:00AM  
Mar-21-21 03:30AM  
Mar-19-21 12:00AM  
Mar-18-21 05:35PM  
04:05PM  
02:30PM  
Mar-11-21 04:05PM  
Mar-10-21 04:30PM  
Feb-22-21 04:05PM  
Feb-03-21 11:36PM  
Jan-06-21 08:00AM  
Jan-01-21 07:04AM  
Dec-21-20 10:07AM  
Dec-20-20 11:29PM  
Dec-17-20 08:00AM  
Dec-11-20 10:23PM  
08:00AM  
Dec-08-20 08:35AM  
Nov-24-20 04:05PM  
Nov-16-20 04:05PM  
Nov-15-20 07:03AM  
Nov-12-20 04:05PM  
02:30PM  
Nov-05-20 04:05PM  
Oct-28-20 06:32AM  
Sep-15-20 04:05PM  
Sep-08-20 04:05PM  
08:57AM  
Aug-26-20 09:42AM  
Aug-11-20 04:05PM  
Aug-05-20 04:05PM  
Aug-04-20 04:05PM  
Jul-24-20 09:15AM  
Jul-22-20 06:45AM  
Jul-08-20 09:05AM  
07:35AM  
Jun-25-20 12:09PM  
Jun-24-20 08:00AM  
Jun-19-20 11:27AM  
09:32AM  
07:41AM  
Jun-18-20 10:22AM  
08:00AM  
Jun-15-20 08:00AM  
Jun-11-20 06:57AM  
Jun-10-20 03:44PM  
Jun-08-20 08:00AM  
Jun-04-20 08:00AM  
May-29-20 08:00AM  
May-26-20 04:05PM  
May-16-20 08:11AM  
May-14-20 04:01PM  
Apr-27-20 09:00AM  
Apr-20-20 04:05PM  
Apr-13-20 06:15AM  
Apr-07-20 07:06AM  
Mar-30-20 04:01PM  
02:30PM  
Mar-18-20 07:15AM  
Mar-02-20 04:05PM  
Feb-25-20 04:02PM  
Jan-24-20 07:30AM  
Jan-14-20 06:17AM  
Jan-06-20 07:30AM  
Dec-22-19 01:52PM  
Dec-09-19 07:30AM  
Nov-26-19 07:30AM  
07:30AM  
Nov-13-19 04:05PM  
07:10AM  
Nov-12-19 07:30AM  
Nov-08-19 07:00AM  
Nov-06-19 09:08AM  
Oct-30-19 07:30AM  
Oct-20-19 08:57AM  
Oct-02-19 07:30AM  
Sep-17-19 07:30AM  
Aug-21-19 01:00PM  
Aug-13-19 07:30AM  
Aug-01-19 10:32AM  
Jun-23-19 10:30AM  
10:27AM  
Jun-03-19 07:35AM  
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GOLD MITCHELLExecutive Chairman and CEOMay 20Sale15.001,22118,316177,853May 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOMay 19Sale15.0350,965765,917179,074May 21 05:16 PM
GOLD MITCHELLExecutive Chairman and CEOMay 13Sale11.5210,000115,169230,039May 14 05:17 PM
GOLD MITCHELLExecutive Chairman and CEOMay 12Sale11.6810,000116,842240,039May 14 05:17 PM
GOLD MITCHELLExecutive Chairman and CEOApr 14Sale10.5210,000105,200250,039Apr 15 06:09 PM
GOLD MITCHELLExecutive Chairman and CEOApr 13Sale10.0710,000100,714260,039Apr 15 06:09 PM
Venkatesan JayDirectorMar 31Option Exercise3.627,65027,718218,063Apr 23 06:14 PM
Venkatesan JayDirectorMar 30Option Exercise4.097,65031,288210,413Apr 23 06:14 PM
GOLD MITCHELLExecutive Chairman and CEOMar 05Sale12.9910,000129,875270,039Mar 08 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOMar 04Sale13.0110,000130,108280,039Mar 08 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOFeb 02Sale11.7410,000117,381290,039Feb 03 05:01 PM
GOLD MITCHELLExecutive Chairman and CEOFeb 01Sale12.8710,000128,665300,039Feb 03 05:01 PM
ORBIMED ADVISORS LLCDirectorDec 28Sale14.25600,0008,550,0003,070,955Dec 30 04:44 PM
Thompson Peter A.DirectorDec 28Sale14.25600,0008,550,0003,070,955Dec 30 04:38 PM
CONWAY ROBERT EDirectorNov 19Buy8.0310,00080,30025,000Nov 23 05:00 PM